PTC sees $960M-$990M 2026 product revenue as Sephience expands and ST-920 filing targets Q4 2026 (NASDAQ:PTCT)
· seekingalpha.com
PTC Therapeutics Q3 2026 earnings: raised revenue guidance, Sephience growth, and ST-920 launch plans.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...